Long‐term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry. Issue 6 (27th July 2020)

• Record Type: Journal Article
• Authors: Semplicini, Claudio; De Antonio, Marie; Taouagh, Nadjib; Béhin, Anthony; Bouhour, Françoise; Echaniz‐Laguna, Andoni; Magot, Armelle; Nadaj‐Pakleza, Aleksandra; Orlikowski, David; Sacconi, Sabrina; Salort‐Campana, Emmanuelle; Solé, Guilhem; Tard, Céline; Zagnoli, Fabien; Hogrel, Jean‐Yves; Hamroun, Dalil; Laforêt, Pascal
• Is Part Of: Journal of inherited metabolic disease. Volume 43:Issue 6(2020)
• Page Start: 1219
• Page End: 1231
• Publication Date: 2020-07-27
• Subjects: alglucosidase alfa -- enzyme replacement therapy -- late onset Pompe disease -- Registry -- Glycogen storage disease type II; Metabolism, Inborn errors of -- Periodicals; Metabolism -- Disorders -- Periodicals; 616.39042
• DOI: 10.1002/jimd.12272
• Languages: English
• ISSNs: 0141-8955

Abstract

Abstract: Despite a wide clinical spectrum, the adult form of Pompe disease is the most common one, and represents more than 90% of diagnosed patients in France. Since the marketing of enzyme replacement therapy (alglucosidase alfa, Myozyme), all reports to date in adults demonstrated an improvement of the walking distance, and a trend toward stabilization of respiratory function, but the majority of these studies were less than 5 years of duration. We report here the findings from 158 treated patients included in the French Pompe Registry, who underwent regular clinical assessments based on commonly used standardized tests (6‐minute walking test, MFM scale, sitting vital capacity, MIP and MEP). For longitudinal analyses, the linear mixed effects models were used to assess trends in primary endpoints over time under ERT. A two‐phase model better described the changes in distance traveled in the 6‐minute walk test and MFM. 6MWT showed an initial significant increase (1.4% ± 0.5/year) followed by a progressive decline (−2.3%/year), with a cut‐off point at 2.2 years. A similar pattern was observed in total MFM score (6.6% ± 2.3/year followed by a − 1.1%/year decline after 0.5 years). A single‐phase decline with a slope of −0.9 ± 0.1%/year ( P < .001) was observed for FVC, and MEP remained stable over the all duration of follow‐up. This study provides further evidence that ERT improves walking abilities and likely stabilizes respiratory function in adult patients with Pompe disease, with a ceiling effect for the 6MWT in the first 3 years of treatment.